XS228 / Xellsmart Biomedical - LARVOL DELTA

Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

New P2 trial • CNS Disorders • Orthopedics • Transplantation

Safety and Early Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

New P1 trial • CNS Disorders • Orthopedics • Transplantation

XellSmart’s Allogeneic iPSC-derived Cell Therapies for Parkinson’s Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials (PRNewswire) - "...the FDA also granted XellSmart a special exemption to support the clinical trial of XellSmart's cell therapy for PD in the US....The approval of XellSmart's clinical trial, along with the special exemption granted, signifies the FDA's recognition of XellSmart's well-established clinical-grade iPSC-derived cell drug development, production, and quality control systems, as well as its completed preclinical safety and efficacy studies....Additionally, XellSmart's allogeneic, off-the-shelf iPSC-derived dopaminergic neural progenitor cell injection ('XS-411 Injection') has also been approved by China's National Medical Products Administration (NMPA) to enter Phase I clinical trials....XellSmart's off-the-shelf, allogeneic, clinical-grade iPSC-derived cell therapy (XS228) for ALS has been approved by the FDA to enter Phase I clinical trials, making it the first-in-class regenerative neural cell therapy for ALS."

New P1 trial • Amyotrophic Lateral Sclerosis • Parkinson's Disease